Entrada Therapeutics price target lowered to $20 from $25 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Entrada Therapeutics to $20 from $25 and keeps a Buy rating on the shares. The analyst says discrepancies in regulatory receptivity in different territories create challenges in evaluating ENTR-601-44’s prospects. The firm remains bullish about ENTR-601-44’s regulatory approval and commercialization in the U.S. and other geographies, but lowered its overall probability of approval from 30% to 20% based on the company’s inability to secure alignment with the agency’s requirements.